|Bid||8.80 x N/A|
|Ask||8.95 x N/A|
|Day's range||8.75 - 8.75|
|52-week range||6.45 - 26.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||17 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Exscientia plc ( NASDAQ:EXAI ) shareholders should be happy to see the share price up 12% in the last week. But that's...
VIENNA & OXFORD, England, September 20, 2022--Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled "Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing" from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the transformative work of the EXALT-1 t
OXFORD, England, September 08, 2022--Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia’s People (human resources) and Places functions and build on the Company’s talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil.